Evaluation of alternate categorical tumor metrics and cut points for response categorization using the RECIST 1.1 data warehouse

Journal of Clinical Oncology

Volumn 32, Issue 8, 2014, Pages 841-850

  Mandrekar, Sumithra J ^a   An, Ming Wen ^b   Meyers, Jeffrey ^a   Grothey, Axel ^a   Bogaerts, Jan ^c   Sargent, Daniel J ^a  

^a MAYO CLINIC   (United States)

^b VASSAR COLLEGE   (United States)

^c EORTC DATA CENTER   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CLASSIFICATION; CANCER SURVIVAL; CLASSIFICATION; COLORECTAL CANCER; DATA BASE; EVALUATION STUDY; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; BREAST TUMOR; COLORECTAL TUMOR; DECISION SUPPORT SYSTEM; DISCRIMINANT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; LUNG TUMOR; MALE; METASTASIS; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; REMISSION; REPRODUCIBILITY; RISK FACTOR; TIME; TREATMENT OUTCOME; VALIDATION STUDY;

BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DECISION SUPPORT SYSTEMS, CLINICAL; DECISION SUPPORT TECHNIQUES; DISCRIMINANT ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84899649956     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.3019     Document Type: Article

References (18)

1. Kola I, Landis J: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-715, 2004 (Pubitemid 39173511)
2. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
3. Bogaerts J, Ford R, Sargent D, et al: Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 45:248-260, 2009
4. Lavin PT: An alternative model for the evaluation of antitumor activity. Cancer Clin Trials 4:451-457, 1981
5. Dhani N, Tu D, Sargent DJ, et al: Alternate endpoints for screening phase II studies. Clin Cancer Res 15:1873-1882, 2009
6. Pivot X, Thierry-Vuillemin A, Villanueva C, et al: Response rates: A valuable signal of promising activity? Cancer J 15:361-365, 2009
7. Heun JM, Grothey A, Branda ME, et al: Tumor status at 12 weeks predicts survival in advanced colorectal cancer: Findings from NCCTG N9741. Oncologist 16:859-867, 2011
8. Lara PN Jr, Redman MW, Kelly K, et al: Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials. J Clin Oncol 26:463-467, 2008 (Pubitemid 351171700)
9. Mandrekar SJ, Qi Y, Hillman SL, et al: Endpoints in phase II trials for advanced non-small cell lung cancer. J Thorac Oncol 5:3-9, 2010
10. Foster NR, Qi Y, Shi Q, et al: Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: Findings on the basis of North Central Cancer Treatment Group trials. Cancer 117:1262-1271, 2011
11. An MW, Mandrekar SJ, Branda ME, et al: Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res 17:6592-6599, 2011
12. Hillman SL, An MW, O'Connell MJ, et al: Evaluation of the optimal number of lesions needed for tumor evaluation using the Response Evaluation Criteria in Solid Tumors: A North Central Cancer Treatment Group investigation. J Clin Oncol 27:3205-3210, 2009
13. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996 (Pubitemid 26072233)
14. Harrell FE Jr, Califf RM, Pryor DB, et al: Evaluating the yield of medical tests. JAMA 247: 2543-2546, 1982 (Pubitemid 12155954)
15. Antolini L, Boracchi P, Biganzoli E: A time-dependent discrimination index for survival data. Stat Med 24:3927-3944, 2005 (Pubitemid 43115739)
16. Newson RB: Comparing the predictive powers of survival models using Harrell's C or Somers' D. Stata J 10:339-358, 2010
17. Suzuki C, Blomqvist L, Sundin A, et al: The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy. Ann Oncol 23:948-954, 2012
18. Claret L, Gupta M, Han K, et al: Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. J Clin Oncol 31:2110-2114, 2013